semaglutide and hormone replacement therapy Therapy: What Perimenopausal Patients Should Know A new study found postmenopausal

After 5 weeks, remaining amounts are negligible and no longer produce meaningful effects

For GLP-1 users, this is especially important given the risk of lean muscle mass decline

Determining an appropriate GLP-1 receptor agonist hinges on various factors including personal preference, financial considerations, administration frequency, along with specific health conditions that patients might have

In eight breast cancer patients with a median of six prior therapies treated at the cohort expansion recommended dose, an ORR of 13% was observed (1 of 8 patients).Toxicity analysis revealed two cases of G2 keratitis lasting more than 14 days

Major schedule changes should be discussed with your prescriber, especially during dose titration